Masitinib mesylate
Masitinib mesylate is in phase III clinical trials for the treatment of cutaneous mastocytosis, systemic mastocytosis asthma, amyotrophic lateral sclerosis, Alzheimer's disease, rheumatoid arthritis, multiple sclerosis, multiple myeloma, melanoma, metastatic colorectal cancer and pancreas cancer.
It was granted orphan drug designation by FDA for the treatment of pancreatic cancer and amyotrophic lateral sclerosis, respectively, in 2009 and 2015.
General Information
Update Date：2015-11-09
- Drug Name：
- Masitinib mesylate
- Research Code：
- AB-1010
- Trade Name：
- MOA：
- PDGFR inhibitor
- Indication：
- Multiple myeloma (MM); Gastrointestinal stromal tumors (GISTs); Prostate cancer
- Status：
- NDA Filing (EU)
- Company：
- AB Science (Originator)
- Sales：
- ATC Code：
- L01XE22
Chemical Structure
Update Date：2015-08-27
|
Molecular Weight | 594.75 | ||||||||||||
| Formula | C28H30N6OS ● CH4O3S | |||||||||||||
| CAS No. |
790299-79-5 (Masitinib); 1048007-93-7 (Masitinib Mesylate); |
|||||||||||||
| Chemical Name | Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-, methanesulfonate (1:1) | |||||||||||||
| Masitinib （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2015-10-15
